Because of the observed negative associations with overweight and obesity and the beneficial metabolic properties, CTRP-3 might be considered both as a potential biomarker and future drug target in the context of the metabolic syndrome, especially in obesity and T2D. The gene discussed is C1QTNF3; the disease is obesity due to melanocortin 4 receptor deficiency.